Amphastar Pharmaceuticals (AMPH) Releases Earnings Results, Beats Estimates By $0.03 EPS

Amphastar Pharmaceuticals (NASDAQ:AMPH) posted its quarterly earnings data on Monday. The company reported $0.10 EPS for the quarter, topping the Zacks’ consensus estimate of $0.07 by $0.03, Briefing.com reports. Amphastar Pharmaceuticals had a net margin of 0.12% and a return on equity of 2.30%. The company had revenue of $60.40 million during the quarter, compared to the consensus estimate of $60.62 million. During the same period in the prior year, the business posted $0.01 EPS. The company’s quarterly revenue was down 4.9% on a year-over-year basis.

Shares of Amphastar Pharmaceuticals (AMPH) traded up $0.44 during mid-day trading on Monday, hitting $19.58. 221,774 shares of the stock were exchanged, compared to its average volume of 185,731. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.86 and a current ratio of 3.08. The company has a market cap of $900.21, a PE ratio of 127.60, a price-to-earnings-growth ratio of 1.34 and a beta of 1.46. Amphastar Pharmaceuticals has a 12 month low of $12.05 and a 12 month high of $19.95.

In other news, Director Stephen B. Shohet sold 7,866 shares of the company’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $18.87, for a total value of $148,431.42. Following the sale, the director now directly owns 31,982 shares of the company’s stock, valued at approximately $603,500.34. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Jason B. Shandell sold 8,661 shares of the company’s stock in a transaction dated Thursday, January 25th. The shares were sold at an average price of $19.26, for a total transaction of $166,810.86. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 36,200 shares of company stock worth $697,083. 11.10% of the stock is owned by insiders.

A number of equities analysts have recently commented on AMPH shares. BidaskClub downgraded shares of Amphastar Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, January 9th. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. Piper Jaffray Companies restated a “buy” rating and set a $26.00 price objective on shares of Amphastar Pharmaceuticals in a research note on Tuesday, January 30th. Finally, Needham & Company LLC upped their target price on shares of Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a report on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $20.83.

ILLEGAL ACTIVITY WARNING: “Amphastar Pharmaceuticals (AMPH) Releases Earnings Results, Beats Estimates By $0.03 EPS” was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.themarketsdaily.com/2018/03/13/amphastar-pharmaceuticals-amph-releases-earnings-results-beats-estimates-by-0-03-eps.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Earnings History for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply